NICE IDs

28/08/2026

ID6618: Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1

26/08/2026

ID6596: Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable

14/08/2026

ID6499: Insulin efsitora alfa for treating type 2 diabetes

11/08/2026

ID6537: Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years

11/08/2026

ID6510: 12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years

31/07/2026

ID6232: Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia

29/07/2026

ID6155: Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma

29/07/2026

ID6413: Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments

28/07/2026

ID6451: Nemolizumab for treating prurigo nodularis

24/07/2026

ID6326: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA779)

24/07/2026

ID6457: Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over

03/07/2026

ID1627: Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia

26/06/2026

ID6575: Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy

19/06/2026

ID6597: Deuruxolitinib for treating severe alopecia areata

16/06/2026

ID6610: Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901)

15/06/2026

ID6487: Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis

05/06/2026

ID6287: Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781)

05/06/2026

ID6269: Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor

02/06/2026

ID3843: Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable

01/06/2026

ID6259: Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes